Biomarin Pharmaceutical Inc

Healthcare · Biotechnology

54.80$ -0.2% vs. previous close Closing price · As of: Oct 9, 2026

Statements

Income Statement

Biomarin Pharmaceutical Inc (BMRN) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Revenue" came in at 990 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size % Per share

Last 12 Full history

Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Income Statement BMRN
Line item	Q3 16	Q4 16	Q1 17	Q2 17	Q3 17	Q4 17	Q1 18	Q2 18	Q3 18	Q4 18	Q1 19	Q2 19	Q3 19	Q4 19	Q1 20	Q2 20	Q3 20	Q4 20	Q1 21	Q2 21	Q3 21	Q4 21	Q1 22	Q2 22	Q3 22	Q4 22	Q1 23	Q2 23	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26	LTM
Revenue	280	300	304	317	334	358	373	373	392	353	401	388	461	454	502	429	477	452	486	502	409	450	519	534	505	538	596	595	581	646	649	712	746	747	745	825	776	875	766	990	3,407
Cost of Revenue	51	64	50	56	59	76	82	79	79	75	89	77	97	96	111	98	189	126	120	127	104	120	117	123	116	127	135	131	128	135	125	130	188	136	152	150	140	295	195	203	833
Gross Profit	229	236	254	261	275	282	291	294	313	278	312	310	364	359	391	332	288	326	366	375	305	330	402	411	389	410	461	465	453	511	524	582	557	611	594	675	636	579	571	787	2,574
Research & Development	161	175	145	143	154	169	184	176	161	175	184	186	173	173	142	182	147	157	149	161	158	161	161	158	158	173	172	177	191	206	205	184	185	174	159	161	409	192	179	207	988
Selling, General & Administrative	119	143	120	144	64	160	138	153	149	164	162	73	170	188	92	78	78	196	80	83	86	105	90	87	106	121	105	91	51	142	107	140	145	141	104	110	137	802	133	253	1,326
Total Operating Expenses	289	326	274	300	288	224	335	319	329	316	366	352	360	368	286	372	344	371	341	363	358	396	265	372	391	435	399	399	423	497	435	461	443	450	370	398	683	500	442	676	2,300
Operating Income	-60	-90	-20	-39	-14	58	-44	-25	-16	-38	-54	-41	4.0	-9.2	105	-41	-56	-45	25	12	-53	-66	137	39	-2.4	-25	62	66	31	14	88	120	114	161	224	277	-47	79	130	111	273
Interest Expense	10.0	9.7	10	10	11	12	12	12	12	7.7	6.7	6.9	2.9	6.9	6.9	8.0	9.6	4.7	3.8	3.8	3.9	3.8	3.8	3.9	4.7	3.6	3.7	3.8	3.8	6.1	3.5	3.6	3.0	2.6	2.9	2.7	2.6	2.8	15	63	84
Pre-Tax Income	-67	-92	-24	-46	-21	55	-51	-29	-19	-43	-53	-42	9.8	-9.8	101	-42	-61	-40	23	14	-46	-67	134	35	-1.9	-18	57	71	42	19	106	132	134	170	238	298	-26	-27	141	61	149
Income Tax Expense	-29	-13	-8.0	-8.7	-8.1	106	-6.7	-12	-6.8	-40	3.5	-4.5	-45	-25	20	-13	-846	-62	5.9	1.2	-9.7	-8.7	13	7.2	4.7	-17	5.9	15	1.3	-1.0	17	25	28	45	52	57	4.4	19	36	17	76
Net Income	-37	-79	-16	-37	-13	-51	-44	-17	-13	-3.7	-56	-37	55	15	81	-29	785	22	17	13	-36	-58	121	28	-6.7	-0.2	51	56	40	20	89	107	106	125	186	241	-31	-47	106	45	73
EBITDA	-28	-63	4.3	-17	9.8	94	-17	3.0	18	-11	-24	-9.2	43	22	134	-9.5	-25	-8.1	55	45	-15	-37	165	64	28	10	87	100	71	52	136	162	156	195	263	319	-5.3	-3.9	173	222	386

LTM = last twelve months (sum of the four most recent quarters).

Showing the most recent 40 periods — older statements are on file for this stock.

Data as of: October 9, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Income Statement

Cookie settings